Literature DB >> 24837882

Antivirals for influenza: where now for clinical practice and pandemic preparedness?

Jonathan S Nguyen-Van-Tam1, Peter J M Openshaw2, Karl G Nicholson3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24837882     DOI： 10.1016/S0140-6736(14)60726-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water.

Authors:  Anna Gillman; Marie Nykvist; Shaman Muradrasoli; Hanna Söderström; Michelle Wille; Annika Daggfeldt; Caroline Bröjer; Jonas Waldenström; Björn Olsen; Josef D Järhult
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

2.  Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness.

Authors:  Sudhir Venkatesan; Cristina Carias; Matthew Biggerstaff; Angela P Campbell; Jonathan S Nguyen-Van-Tam; Emily Kahn; Puja R Myles; Martin I Meltzer
Journal:  J Public Health (Oxf)       Date:  2019-06-01       Impact factor: 2.341

3.  Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected With Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis.

Authors:  Sudhir Venkatesan; Puja R Myles; Jo Leonardi-Bee; Stella G Muthuri; Malak Al Masri; Nick Andrews; Carlos Bantar; Gal Dubnov-Raz; Patrick Gérardin; Evelyn S C Koay; Tze Ping Loh; Ziad Memish; Elizabeth Miller; Maria E Oliva; Barbara A Rath; Brunhilde Schweiger; Julian W Tang; Dat Tran; Tjasa Vidmar; Pauline A Waight; Jonathan S Nguyen-Van-Tam
Journal:  Clin Infect Dis       Date:  2017-05-15       Impact factor: 9.079
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.